Recent New Grants or Comeptitive Renewals

Below is a table of research grant awards for SKCC Members from external funding organizations since 9/1/13
(as presented at 4/30/14 All Hands Meeting)


PI(s) Title Type Annual Total Costs
Dr. Alnemri
(TJU)
Caspase-1 Activation by the Inflammasomes NIH R01 Renewal $500,359
Dr. Alugupalli
(TJU)
Induction of Polysaccharide Vaccine Responses in The Young By Interleukin-7 New NIH R03 $77,500
Dr. Block
(Drexel)
A Small Molecule for Management of Filovirus Hemorrhagic Fevers New NIH R01 $873,245
Dr. Calabretta
(TJU)
Targeting The C/EBPα-Gfi-pathway in CML Stem Cells New NCI R01 $321,625
Dr. Fatatis
(Drexel)
In Vivo Study of Chemokine Antagonists for Cancer New NCI R21 $231,750
Dr. Fong
(TJU)
Chemoprevention of Upper Aerodigestive Tract Cancer by Dietary Zinc New AICR Grant $82,500
Dr. Jiang
(TJU)
Molecular Mechanism of Arsenic Carcinogenesis New NIH R01 $365,365
Dr. Jimenez
(TJU)
Role of TRPV Channels in the Pathogenesis of Systemic Sclerosis Vasculopathy New NIH R01 $204,600
Dr. Keen
(TJU)
Regulation of Clathrin and Adaptor Function NIH R01 Renewal $313,875
Dr. Knudsen
(TJU)
RB Function in Prostate Cancer Progression New NCI R01 $431,269
Dr. Knudsen
(TJU)
Co-Targeting the Cell Cycle And Androgen Signaling Axis Via CDK4/6 Inhibition: A Novel Paradigm for Treating Metastatic Hormone-Sensitive Prostate Cancer Prostate Cancer Rsrch Fdn. $150,000
Dr. Knudsen
(TJU)
African American Research Initiative: The Detrimental Impact of Endogenous Interferons in Prostate Cancer Prostate Cancer Rsrch Fdn. $85,000
Dr. Knudsen
(TJU)
Targeting DNA Repair Alterations to Improve Treatment for Advanced Prostate Cancer Prostate Cancer Rsrch Fdn. $110,000
Dr. Martinez Outschoorn
(TJU)
Metabolic Mechanisms of Antiestrogen Resistance in Breast Cancer New NCI K08 $167,718
Dr. Mehta
(Drexel)
Identification Of Altered Glycan And Glycoproteins In Viral Induced Liver Cancer NCI R01 Suppl. $203,178
Dr. Meucci
(Drexel)
Role of Chemokine Receptors in Neuronal Survival NIH R01 Renewal $309,000
Dr. Pestell
(TJU)
DACH1/EYA Cell Fate Determination Factor And Mammary Tumorigenesis NCI R01 Renewal $311,976
Dr. Radice
(TJU)
N-Cadherin and Metastatic Dissemination New NCI R21 $168,563
Dr. Rui
(TJU)
Molecular Features of Patient-derived Luminal Breast Cancer Xenotransplant Model New NCI R21 $202,275
Dr. Rui
(TJU)
Overcoming Hormone Therapy Resistance in Metastatic Breast Cancer Breast Ca Rsrch. Fdn $100,000
Dr. Reginato
(Drexel)
Understanding Role of O-GlcNAcylation on Cancer Cell Metabolism and Survival
(Trainee: C. Ferrer)
New NCI F31 $41,693
Dr. Snyder
(TJU)
Selection of Inflationary and Tissue-resident T Cells During MCMV Infection New NIH R01 $163,913
Dr. Uitto
(TJU)
Pharmacologic Intervention of PXE Phenotypes New NIH R21 $204,600
Dr. Uitto
(TJU)
Model Systems for PXE NIH R01 Renewal $202,275
Dr. Wu
(TJU)
The Role of Retinal Determination Gene Network (RDGN) in Hormone Signaling Transduction and Prostate Tumorigenesis DOD Renewal $150,000


NCI Designated Cancer Center

Maintained by the Informatics Shared Resources of the Sidney Kimmel Cancer Center at Jefferson

Copyright © Thomas Jefferson University. All Rights Reserved.

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement